the fy16 defense appropriations act provides $12million (m) to the department of defense reconstructive transplant research program (rtrp) to support research of exceptional scientific merit that has the potential to make a significant impact on improving the function, wellness, and overall quality of life for injured military service members and veterans, their caregivers and family members, and the american public.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy16 rtrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

focus areas:  the fy16 rtrp encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (vca) in the following focus areas:

1. immune system regulation as specifically applied to vca
2. improve ex vivo vca tissue preservation techniques or technologies to extend the time between procurement and transplantation (goal: 24 hours)
3. reconstructive transplantation rehabilitation
4. graft surveillance – acute and chronic clinical monitoring
5. psychosocial issues associated with vca

 

http://cdmrp.army.mil/funding/rtrp.shtml

 

concept award – letter of intent due 11/23/16

• independent investigators at all academic levels (or equivalent)
• pre-application (letter of intent) is required.
• funds the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
• preliminary data are not allowed.
• reviewers at both tiers of review will be blinded to the identity of the principal investigator (pi), collaborators, and their organizations.
• applications must address one or more of the fy16 rtrp focus areas 1 through 4 as noted above.

·         maximum funding of $200,000 for total costs

• maximum period of performance is 18 months

 

investigator-initiated research award – preproposal due 9/21/16

• independent investigators at all academic levels (or equivalent)
• preproposal is required; full application submission is by invitation only.
• support studies that have the potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life
• preliminary or published data required.
• partnering pi option supports synergistic partnerships among two to four independent investigators collaborating on a single application.
• applications must address one or more of the fy16 rtrp focus areas 1 through 4 as noted above.

·         individual pis:

·         maximum funding of $1 million (m) for total costs

·         maximum period of performance is 3 years

• partnering pi option:

·         maximum funding of $1.5m for total costs

• maximum period of performance is 3 years.

 

technology development award (tda) – preproposal due 9/21/16

• independent investigators at all academic levels (or equivalent)
• preproposal is required; full application submission is by invitation only.
• supports translation of promising preclinical findings into products.
• proof of concept should already be established.
• preliminary or published data required.
• applications must address one or more of the fy16 rtrp tda focus areas:

·         improve ex vivo vca tissue preservation techniques or technologies

• graft surveillance – acute and chronic clinical monitoring

·         maximum funding of $1m for total costs

·         maximum period of performance is 3 years

 

qualitative research award (qra) – preproposal due 9/21/16

• independent investigators at all academic levels (or equivalent)
• preproposal is required; full application submission is by invitation only.
• supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering, or have already received, reconstructive transplant surgery.
• theoretical perspective of qualitative research must be identified.
• rigorous and appropriate data collection and data analyses methods are important components.
• applications must address one or more of the fy16 rtrp qra focus areas:

·         psychosocial issues associated with vca

·         development and validation of quality of life outcome measures for vca

• partnering pi option supports synergistic partnerships among two to four independent investigators collaborating on a single application.

·         individual pis:

·         maximum funding of $1m for total costs

·         maximum period of performance is 3 years

·         partnering pi option:

·         maximum funding of $1.5m for total costs

• maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released go to the cdmrp website (http://cdmrp.army.mil) and select subscribe to funding opportunities & program communications.  for more information about the rtrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fiscal year 2016 (fy16) defense appropriations act provides $120 million (m) to the department of defense breast cancer research program (bcrp) to support innovative, high-impact breast cancer research to accelerate progress toward ending breast cancer. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy16 bcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov.

applications submitted to the fy16 bcrp must address one or more of the following overarching challenges:

·         prevent breast cancer (primary prevention)

·         identify determinants of breast cancer initiation, risk, or susceptibility

·         distinguish deadly from indolent breast cancer

·         conquer the problems of overdiagnosis and overtreatment

·         identify what drives breast cancer growth; determine how to stop it

·         identify why some breast cancers become metastatic

·         determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to prevent recurrence

·         revolutionize treatment regimens by replacing them with ones that are more effective and less toxic

·         eliminate the mortality associated with metastatic breast cancer

http://cdmrp.army.mil/funding/bcrp.shtml

 

breakthrough award – preapplication due november 3, 2016

 

funding levels 1 and 2:

• investigators at all academic levels (or equivalent)
• postdoctoral fellows are eligible and encouraged to apply
• funding level 1: innovative, high-risk/high-reward research that is in the earliest stages of idea development. research with potential to yield new avenues of investigation. proof of concept. no preliminary data required.
• funding level 2: research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation.
• submission of a letter of intent is required prior to full application submission.
• each pi may submit only one application as a pi or initiating pi. there are no limitations on the number of applications for which an investigator may be named as a partnering pi. however, applicants are discouraged from submitting as a partnering pi on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
• additional funds are available for applications submitted under the partnering pi option.
• clinical trials are not allowed.

funding level 1:

• maximum funding of $375,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 1 - partnering pi option:

• maximum funding of $600,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 2:

• maximum funding of $750,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 2 - partnering pi option:

• maximum funding of $1 million (m) for direct costs (plus indirect costs)
• maximum period of performance is 3 years

 

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that are available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

applications must be submitted through the federal government's single-entry portal, grants.gov. submission deadlines are not available until the program announcements are released. for email notification when program announcements are released go to the cdmrp website (http://cdmrp.army.mil) and select subscribe to funding opportunities & program communications. for more information about the bcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fiscal year 2016 (fy16) defense appropriations act provides $30 million (m) to the department of defense peer reviewed orthopaedic research program (prorp) to support innovative, high-impact orthopaedic research.  the goal of the prorp is to provide all warriors affected by orthopaedic injuries sustained in the defense of our constitution the opportunity for optimal recovery and restoration of function.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy16 prorp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website

focus areas:  the prorp considers applications that specifically address the critical needs of the orthopaedic research community in one or more of the fy16 prorp focus areas.  the prorp will solicit research applications that address at least one of the following fy16 focus areas (note:  focus area requirements vary by award mechanism):

surgical care focus areas:

·         peripheral nerve injuries:  treatment strategies to improve outcomes from segmental peripheral nerve defects of motor and mixed (motor and sensory) peripheral nerve damage from crush or complete injury.

·         prevention of heterotopic ossification:  techniques to retard or prevent the development of human post-traumatic heterotopic ossification in the upper extremity.

·         volumetric muscle loss:  techniques to regenerate functional, innervated muscle units in treatment of volumetric muscle loss.

·         extremity fractures:  strategies to optimize patient outcomes after extremity fracture, i.e., time to begin rehabilitation, weight-bearing strategy.

·         pelvic ring injuries:  treatment strategies to improve outcomes of complex pelvic ring injuries.

·         compartment syndrome:  strategies to improve current diagnoses for compartment syndrome.

·         gaps in clinical practice guidelines:  address gaps in current orthopaedic clinical practice guidelines (cpg) and recommendations (http://www.usaisr.amedd.army.mil/cpgs.html).  applications under this focus area must specify which orthopaedically relevant cpg their application is intended to support.  applicants should also highlight the expected impact of their research on orthopaedic clinical practice.

·         surgical techniques to optimize gait:  identify surgical techniques to optimize gait efficiency and outcomes for patients with amputation or limb salvage.

·         soft tissue trauma:  strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments affecting return to duty, work, or reintegration.

rehabilitation focus areas:

·         post-operative pain management:  develop strategies for post-operative pain management following orthopaedic trauma that minimize or eliminate opioid use.  the primary outcome measures should relate to rehabilitation endpoints and not focus solely on pain scores.

·         prosthetic and/or orthotic device function:  development and optimization of novel and/or innovative technologies to improve prosthetic and/or orthotic device function and durability, including intuitive efferent and afferent user interfaces and considerations to interoperability.

·         secondary physical health effects:  techniques or technologies that improve prediction, identification, and reduction of secondary physical health effects (e.g., obesity, arthrosis, osteoporosis, cardiovascular disease) following severe/high-energy traumatic neuromusculoskeletal non-spinal cord injury.  the focus should be on injuries sustained between the ages of 18-50 and secondary physical health effects that develop within 5 years of injury.

·         physical or occupational therapy:  development and/or validation of optimal physical or occupational therapy treatment strategies and sequence of progression throughout the rehabilitation continuum to maximize functional outcomes following severe neuromusculoskeletal injury, excluding central nervous system.  examples include optimal dose, timing, frequency, duration, and intensity of rehabilitation interventions.

·         barriers to successful therapy outcomes:  identify, quantify, and stratify confounding treatable factors (e.g., pain, sleep, nutrition, compliance, etc.) that inhibit or delay optimal orthopaedic rehabilitation outcomes.

·         rehabilitation outcomes:  development of validated, standardized measures to objectively assess and improve rehabilitation outcomes, including multi-extremity trauma and/or psychosocial resiliency and reintegration, following neuromusculoskeletal injury.

 

http://cdmrp.army.mil/funding/prorp.shtml

 

applied research award – preapplication due september 7, 2016

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·        pre-application is required; full application submission is by invitation only.

·        supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities

·        applications must address one and only one of the fy16 prorp focus areas.

·        proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.

clinical trials are not allowed under this award mechanism.

·        maximum funding of $500,000 for total costs (direct costs plus indirect costs)

·        maximum period of performance is 3 years

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

 

clinical trial award – preapplication due september 7, 2016

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·        pre-application is required; full application submission is by invitation only.

·        supports the rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates

·        applications must address one and only of the fy16 prorp focus areas.

·        funding must support a clinical trial and may not be used for preclinical research studies.

·        collaboration with military researchers and clinicians is encouraged.

·        studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·        maximum funding of $3 million (m) for total costs (direct costs plus indirect costs)

·        maximum period of performance is 4 years.

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

integrated clinical trial award - preproposal due 9/7/2016

independent investigators at all academic levels (or equivalent) are eligible to submit applications

·        pre-application is required; full application submission is by invitation only.

·        supports the rapid implementation of inter-disciplinary clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work

·        applications must address at least two (minimum of one surgical care and one rehabilitation) and a maximum of four of the fy16 prorp focus areas.

·        required qualified collaborator: to encourage meaningful and productive multidisciplinary collaborations, there must be at least one investigator with rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care.

·        collaboration with military researchers and clinicians is encouraged.

·        studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·        maximum funding of $4.5m for total costs (direct costs plus indirect costs)

·        maximum period of performance is 4 years.

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

 

clinical translational research award – preproposal due 9/7/2016

independent investigators at all academic levels (or equivalent) are eligible to submit applications

·        pre-application is required; full application submission is by invitation only.

·        supports research that evaluates the effectiveness and functional outcomes of health care practices and interventions for traumatic military or veteran amputee and/or limb salvage patients with the potential to impact the standard of care and contribute to evidence-based policy or guidelines for patient evaluation and care

·        applications must address at least one of the fy16 prorp rehabilitation focus areas.

·        funding must support clinical research studies involving humans.

·        preliminary or published data relevant to the proposed research project are required.

·        collaboration with military researchers and clinicians is encouraged.

·        studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·        maximum funding of $2m for total costs (direct costs plus indirect costs)

·        maximum period of performance is 4 years.

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  applications must be submitted through the federal government’s single-entry portal, grants.gov.   for email notification when program announcements are released go to the cdmrp website (http://cdmrp.army.mil) and select subscribe to funding opportunities & program communications.  for more information about the prorp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

 

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

partnership development grants provide support over one to three years to teams/partnerships, led by a project director, to:

• develop research and related activities in the social sciences and humanities, including knowledge mobilization and the meaningful involvement of 世界杯2022赛程表淘汰赛 and new scholars, by fostering new partnerships for research and related activities involving existing and/or potential partners; or
• design and test new partnership approaches for research and/or related activities that may result in best practices or models that either can be adapted by others or have the potential to be scaled up to a regional, national or international level.

partnerships funding is intended for teams working in formal collaboration between postsecondary institutions and/or organizations of various types.

the specific objectives of this funding opportunity are to:

• develop and build on canada’s mentoring capacity in the early-to-mid career researcher cohort in the area of innovative clinical trials and patient-oriented research.
• train a new generation of researchers to undertake innovative clinical trials and patient-oriented research.

the specific objectives of this funding opportunity are:

1. to support the development or adaptation of innovative and novel work-related, evidence-based, gender-responsive, culturally-appropriate e-mental health solutions that address an identified gap or need.
2. to fund researchers and knowledge users, who will identify challenges and novel solutions to workplace psychological health, to attend a collaborative, solutions-focused e-mental health hackathon.
3. to catalyze the continued work of collaborations established during the hackathon on their e-mental health solutions following the event.

the midcareer grant program was launched in 2014 to enrich the work of academic midcareer scholars who are seven to twenty years post doctorate. this targeted program provides support for those who are interested in advancing their understanding of a compelling problem of education by acquiring new skills, substantive knowledge, theoretical perspectives or methodological tools. grants are for one year with budgets of up to $150,000. read more...

past awards

to learn more about grants made in this program in the past, please go to the grant library here and choose midcareer grant from the "grant type" menu.

deadlines

the deadline for proposal submissions to this program is 4:00pm cdt, september 13, 2016.

the operating grant program is intended to support various research operations in all aspects of multiple sclerosis (ms) and defray the normal operating costs of carrying out a specific research proposal. the ms society welcomes applications that are fundamental as well as applied studies, nonclinical or clinical in nature, including projects in patient management, care and rehabilitation.

based on the nature of the research, the candidate can apply for one of the following awards:

• operating grant: biomedical research
• operating grant: clinical and population health research